<DOC>
	<DOCNO>NCT01665274</DOCNO>
	<brief_summary>The purpose study demonstrate capecitabine/oxaliplatin perioperative chemotherapy superior operation directly locally advanced gastric cancer term 3 year disease-free survival ( DFS ) rate .</brief_summary>
	<brief_title>Efficiency XELOX Neoadjuvant Chemotherapy Gastric Cancer</brief_title>
	<detailed_description>The patient gastric cancer divide two part random.The test group receive perioperative chemotherapy ( XELOX ) six cycle control group administrate program operation . The two group stag eligibility criteria.The 3 year disease-free survival ( DFS ) rate 5 year overall survival ( OS ) rate maybe last evaluation standard .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Karnofsky performance status ≥60 % . Histologically confirm gastric adenocarcinoma , stag pathologically clinically , stage cT24N+M0 , cT4N0M0 . Patients adequate renal function ( serum creatinine ≤1 time upper limit normal [ ULN ] ) , hepatic function ( total bilirubin ≤1·5 time ULN , aspartate alanine aminotransferase ≤2·5 time ULN , alkaline phosphatase ≤2·5 time ULN , Serum albumin ≥30g/L ) , haematological function ( absolute neutrophil count ≥1·5×10⁹/L platelet count ≥100×10⁹/L ) Pregnant lactate woman . According AJCC TMN 7.0 , Any evidence metastatic ( TxNxM1 ) patient ( include presence tumor cell ascites ) . Sexually active male female ( childbearing potential ) unwilling practice contraception study . Previous cytotoxic chemotherapy , radiotherapy immunotherapy except corticosteroid , currently treat gastric cancer . Has uncontrolled epilepsy , central nervous system diseases mental disorder history . Clinically significant ( i.e . active ) cardiac disease e.g . symptomatic coronary artery disease , New York Heart Association ( NYHA ) grade II great congestive heart failure serious cardiac arrhythmia require medication myocardial infarction within last 12 month . Lack physical integrity upper gastrointestinal tract malabsorption syndrome likely influence absorption capecitabine , inability take oral medication . Known peripheral neuropathy ≥ CTCAEv3 grade 1 ( Common Terminology Adverse Events ) . Absence deep tendon reflex sole neurologic abnormality render patient ineligible . Organ allograft require immunosuppressive therapy . Serious uncontrolled intercurrent infection serious uncontrolled concomitant disease . Moderate severe renal impairment [ creatinine clearance equal 50 ml/min ( calculate accord Cockroft Gault ) ] , serum creatinine &gt; 1.5 x upper limit normal ( ULN ) . Any follow laboratory value : Absolute neutrophil count ( ANC ) &lt; 1.5 x 109/L Platelet count &lt; 100 x 109/L Total bilirubin &gt; 1.5 x ULN ALAT , ASAT &gt; 2.5 x ULN Alkaline phosphatase &gt; 2.5 x ULN . Prior unanticipated severe reaction fluoropyrimidine therapy ( without document dihydropyrimidine dehydrogenase ( DPD ) deficiency ) patient know DPD deficiency . Hypersensitivity platinum compound component study medication . Received investigational drug agent/procedure , i.e . participation another trial , within 4 week randomization . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>xelox</keyword>
	<keyword>advanced gastric cancer</keyword>
</DOC>